STOCK TITAN

Hyperfine, Inc. - HYPR STOCK NEWS

Welcome to our dedicated page for Hyperfine news (Ticker: HYPR), a resource for investors and traders seeking the latest updates and insights on Hyperfine stock.

Hyperfine, Inc. (Nasdaq: HYPR) is committed to revolutionizing the field of medical imaging with its pioneering Swoop® Portable MR Imaging System™. By making MRI accessible to every patient, regardless of income or location, Hyperfine is bridging the gap in medical imaging. The Swoop system addresses the limitations of conventional MRI scanners by providing portable, bedside imaging capabilities. This breakthrough technology plugs into a standard electrical outlet and is controlled using an Apple iPad®, displaying images within minutes. This efficiency aids critical decision-making in diverse clinical settings such as neurointensive care units, emergency departments, and pediatric wards.

Designed to complement traditional MRI systems, the Swoop Portable MR Imaging System can be operated by new users with just 30 minutes of training, streamlining workflows and enhancing patient care. The system is cost-effective, with the complete Swoop package costing less than the annual service contract of most fixed MRI systems.

Since receiving FDA clearance in August 2020 for brain and head imaging, Hyperfine has achieved significant milestones. The company has expanded its market reach, gaining approvals in several countries including Canada, Australia, the United Kingdom, and the European Union. Hyperfine’s recent achievements include the successful enrollment in the CARE PMR study for Alzheimer’s and the introduction of its 8th generation AI-powered software.

In the first quarter of 2024, Hyperfine reported strong commercial progress and financial results, demonstrating their ability to meet critical milestones while maintaining spending discipline. The company remains focused on its core values of commercialization, clinical evidence, and innovation. Under the leadership of CEO Maria Sainz, Hyperfine continues to push the boundaries of medical imaging technology, aiming to provide accessible and clinically relevant diagnostic imaging solutions globally.

For more information, visit Hyperfine's Investor Relations.

Rhea-AI Summary
Hyperfine, Inc. announced initial findings from a multicenter study on the use of portable MR brain imaging in assessing acute brain injury in ECMO patients. The study demonstrated the feasibility of using portable MR brain imaging for monitoring patients during ECMO use and highlighted its potential advantage in providing early visualization of ischemic stroke compared to CT scans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.36%
Tags
none
-
Rhea-AI Summary
Hyperfine, Inc. to report financial results for Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
-
Rhea-AI Summary
Hyperfine, Inc. promotes Dr. Edmond Knopp and Dr. Chip Truwit as vice presidents of medical affairs and scientific affairs respectively, highlighting their expertise in radiology and neuroradiology. Dr. Knopp will focus on advancing brain health in stroke care and Alzheimer's therapies, while Dr. Truwit will lead clinical innovation projects. These appointments demonstrate Hyperfine's commitment to developing ultra-low-field MR brain imaging.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
management
Rhea-AI Summary
Hyperfine, Inc. announces FDA clearance of updated software for their Swoop® ultra-low-field brain imaging system, incorporating advanced AI algorithms for image quality enhancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
-
Rhea-AI Summary
Hyperfine, Inc. to present at Gilmartin Group Emerging Growth Showcase on September 21, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.1%
Tags
conferences acquisition
-
Rhea-AI Summary
Hyperfine, Inc. reports Q2 2023 revenue of $3.38M, up from $1.53M in Q2 2022. Net loss for Q2 2023 is $10.64M, compared to $23.16M in Q2 2022. Full-year 2023 revenue expected to be $10-14M. Cash burn for 2023 expected to be $40-45M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.45%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
none

FAQ

What is the current stock price of Hyperfine (HYPR)?

The current stock price of Hyperfine (HYPR) is $0.8851 as of December 20, 2024.

What is the market cap of Hyperfine (HYPR)?

The market cap of Hyperfine (HYPR) is approximately 66.7M.

What is Hyperfine's mission?

Hyperfine’s mission is to make MRI accessible to every patient, regardless of income or resources, anytime, anywhere.

What is the Swoop® Portable MR Imaging System?

The Swoop system is a portable MRI device that wheels directly to a patient's bedside, plugs into a standard outlet, and uses an iPad® for control, displaying images within minutes.

When did Swoop receive FDA clearance?

The Swoop Portable MR Imaging System received FDA clearance in August 2020 for brain and head imaging.

What are the core values of Hyperfine?

Hyperfine's core values focus on commercialization, clinical evidence, and innovation.

How long does it take to train new users on the Swoop system?

New users can be trained on the Swoop system operation, device navigation, and safety in about 30 minutes.

What are the cost benefits of the Swoop system?

The complete Swoop Portable MR Imaging System costs less than the annual service contract for most fixed conventional MRI systems.

Where is the Swoop system currently approved for use?

The Swoop system is approved for use in the United States, Canada, Australia, the United Kingdom, and the European Union.

What recent achievements has Hyperfine made?

Recent achievements include the commencement of the CARE PMR study in Alzheimer's and the launch of the 8th generation AI-powered software.

Who is the CEO of Hyperfine, Inc.?

The CEO of Hyperfine, Inc. is Maria Sainz.

Where can I find more information about Hyperfine?

More information about Hyperfine can be found on their investor relations page at https://investors.hyperfine.io/.

Hyperfine, Inc.

Nasdaq:HYPR

HYPR Rankings

HYPR Stock Data

66.75M
52.43M
9.5%
24.35%
2.14%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
GUILFORD